Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
Purpose
The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant. This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer seizures than required for the Qualifying Seizures Cohort (Phase 3 Cohort 2: Without Qualifying Seizures Auxiliary Cohort). Participants in each cohort will be randomized 1:1 to receive active drug (radiprodil) or matching placebo (Part A). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil. The placebo-controlled portion is expected to be approximately 16 weeks for participants in Phase 3 Cohort 1 and 28 weeks for participants in Phase 3 Cohort 2. The study will evaluate the effect of radiprodil on seizures and non-seizure symptoms and assess safety.
Condition
- GRIN-related Neurodevelopmental Disorder
Eligibility
- Eligible Ages
- Between 1 Month and 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Part A, Participant: - Diagnosed with GRIN-NDD with GRIN1, GRIN2A, GRIN2B, or GRIN2D gene variants known to result in GoF of the NMDA receptor - Phase 3 Cohort 1 (Qualifying Seizures Cohort) ONLY: Experiencing at least 1 CMS per week and ≥4 CMS (generalized or focal) during screening - With history of inadequate response to at least 2 standard antiseizure medications (ASMs) - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort) ONLY: With significant neurodevelopmental symptoms and a GRIN-CGI-S score ≥4 - On a stable dose of standard ASMs for at least 4 weeks prior to screening and should remain on stable doses throughout study participation - On stable nonpharmacological treatments such as ketogenic diet and should remain stable throughout study participation Part B: - Participant has completed Part A and is eligible to continue study participation according to the judgement of the investigator and sponsor.
Exclusion Criteria
PART A, Participant: - Has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation or study drug administration or the conduct of the study according to the judgement of the investigator or sponsor. - Is receiving >4 standard ASMs at screening - Has a body weight of less than 5 kg at screening Part B: - Participant has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation of study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
- Masking Description
- study personnel, sponsor
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Radiprodil |
Liquid suspension of radiprodil, at varying concentrations depending on participant's weight. The following dose-escalation regimen (twice daily [BID]) will be used: Titration Period Visit 1 (Visit T1): Dose 1, Visit T2: Dose 2, Visit T3: Dose 3, Visit T4: Maintenance Dose. |
|
|
Placebo Comparator Placebo |
Liquid suspension of placebo matching radiprodil oral suspension and dose-escalation regimen. |
|
Recruiting Locations
Houston 4699066, Texas 4736286 77030
More Details
- Status
- Recruiting
- Sponsor
- GRIN Therapeutics, Inc.
Detailed Description
Participants are assigned in a 1:1 ratio to receive either radiprodil or placebo during Part A with the opportunity to receive radiprodil in the Open-Label Extension, Part B. The dosing regimen includes a fixed titration schedule over 4 weeks. This study is divided into the following parts: Part A: Randomized, double-blind, placebo-controlled - Screening/Observation Period: To assess eligibility - Titration Period (approximately 4 weeks): Titration of radiprodil or placebo to target dose - Maintenance Period (Part A): Target dose of radiprodil or placebo maintained for 12 weeks (Phase 3 Cohort 1) or 24 weeks (Phase 3 Cohort 2) - Tapering and Follow-up Period: Gradual decrease and Follow-up Period for participants not entering Part B Part B: Open-label safety follow-up period - Open-Label Treatment Period: Participants will continue to receive radiprodil until such time as either the participant withdraws/is withdrawn from the study, sponsor terminates the study, or market access is available - Tapering and Follow-up Period: Gradual decrease and follow-up observation period for participants upon leaving the study